SCHEMBL671826

SCHEMBL671826

CC(C)(C)OC(=O)n1nc(C=O)c2cc(F)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.42
AR P10275 1/20 0.40
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GABRG2 P18507 3/20 0.38
GABRB3 P28472 3/20 0.38
GABRA5 P31644 3/20 0.38
GABRA1 P14867 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRA6 Q16445 2/20 0.38
GABRA3 P34903 1/20 0.38
GABRA4 P48169 1/20 0.38
PLK1 P53350 2/20 0.38
ELANE P08246 1/20 0.36
SSTR4 P31391 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
SCN9A Q15858 1/20 0.33
EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1141277 0.85 GABRG2 (0.48) MAP2K4GABRG2GABRB3GABRA5GABRA1
SCHEMBL5951228 0.84 MAP2K4 (0.39) MAP2K4KDM4EALDH1A1ELANEBRD4
SCHEMBL13375156 0.83 MAP2K4 (0.39) MAP2K4GABRG2GABRB3GABRA5GABRA1
SCHEMBL15169674 0.82 MAP2K4 (0.43) MAP2K4ARGABRG2GABRB3GABRA5
SCHEMBL15541538 0.82 MAP2K4 (0.43) MAP2K4ARGABRG2GABRB3GABRA5
SCHEMBL16800567 0.82 MAP2K4 (0.46) MAP2K4KDM4EGABRG2GABRB3GABRA5
SCHEMBL29443983 0.82 MAP2K4 (0.43) MAP2K4KDM4EALDH1A1ELANENR1H2
SCHEMBL15902469 0.82 MAP2K4 (0.43) MAP2K4KDM4EALDH1A1ELANENR1H2
SCHEMBL5953089 0.81 MAPT (0.38) MAP2K4KDM4EALDH1A1ELANESMN1; SMN2
SCHEMBL787427 0.78 PDGFRA (0.44) MAP2K4GABRG2GABRB3GABRA5ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2605658-B1 SPIROXAZOLIDINONE COMPOUNDS MERCK SHARP & DOHME (US) 2016-03-23 EP disclosed
US-8742110-B2 Spiroxazolidinone compounds MERCK SHARP & DOHME CORP. (US) 2014-06-03 US disclosed
EP-2605658-A1 SPIROXAZOLIDINONE COMPOUNDS Merck Sharp & Dohme Corp. (US) 2013-06-26 EP disclosed
US-20130131042-A1 SPIROXAZOLIDINONE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2013-05-23 US disclosed
WO-2012024183-A1 SPIROXAZOLIDINONE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131042-A1 SPIROXAZOLIDINONE COMPOUNDS SSTR5, SSTR2, SSTR4 MAP2K4 1506/4885AR 307/4885KDM4E 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.